The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis

PURPOSE: Monoclonal antibodies against type 2 inflammatory pathways are currently promising therapeutics for severe asthma. The aim of this study was to determine how well type 2 (T2) inflammation-specific agents targeting interleukins reduce the rate of asthma exacerbations (AE) in patients with se...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jonghoo, Song, Jae-Uk, Kim, Yee Hyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171665/
https://www.ncbi.nlm.nih.gov/pubmed/35619574
http://dx.doi.org/10.3349/ymj.2022.63.6.511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171665/
https://www.ncbi.nlm.nih.gov/pubmed/35619574
http://dx.doi.org/10.3349/ymj.2022.63.6.511

Ejemplares similares